InsidersTradesSigma
Track the BioSig Technologies, Inc. share price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, BioSig Technologies, Inc. has logged 102 public disclosures. The latest transaction was filed on 2 June 2025 (Attribution). Among the most active insiders: LONDONER KENNETH L. The full history is free.
102
Insider Decl.
n/a
Thresholds
€370,102
40 ops.
Buy Volume
n/a
n/a
Sell Volume
32Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 2 June 2025
Declarations102 total
900,000 shares0Common StockSEC:0001641172-25-013288:0
175,000 shares0Common StockSEC:0001641172-25-013287:0
23,345 shares0Common StockSEC:0001641172-25-006563:0
23,345 shares0Common StockSEC:0001641172-25-006564:0
23,345 shares0Common StockSEC:0001641172-25-006568:0
23,345 shares0Common StockSEC:0001641172-25-006565:0
35,000 shares0Common StockSEC:0001641172-25-006566:0
23,345 shares0Common StockSEC:0001641172-25-006567:0
275,000 shares0Common StockSEC:0001493152-24-036198:0
30,000 shares0Common StockSEC:0001493152-24-029663:0
30,000 shares0Common StockSEC:0001493152-24-029661:0
30,000 shares0Common StockSEC:0001493152-24-029664:0
30,000 shares0Common StockSEC:0001493152-24-029662:0
50,000 shares0Common StockSEC:0001493152-24-026333:0
500,000 shares0Common StockSEC:0001493152-24-008758:0
131,900 shares0Common StockSEC:0001493152-23-043760:0
92,300 shares0Common StockSEC:0001493152-23-043762:0
219,700 shares0Common StockSEC:0001493152-23-043614:0
16,000 shares0Common StockSEC:0001185185-23-000883:0
12,000 shares0Common StockSEC:0001185185-23-000875:0
16,000 shares0Common StockSEC:0001185185-23-000885:0
12,000 shares0Common StockSEC:0001185185-23-000879:0
16,000 shares0Common StockSEC:0001185185-23-000877:0
16,000 shares0Common StockSEC:0001185185-23-000881:0
10,000 shares@ US$1.241.7% of flowCommon StockSEC:0001185185-23-000633:0
Canonical exit: 11 Sept 2023 (T+90)
25 of 102 declarations
关于 BioSig Technologies, Inc.
BioSig Technologies, Inc.（股票代码：BSGM）是一家总部位于美国的上市公司，在美国纳斯达克市场上市。历史上，BioSig 定位为一家医疗技术公司，专注于其 PURE EP™ 平台，该平台是一个数字信号处理系统，旨在改善心内信号可视化，供电生理学家在进行心律失常消融手术时使用。实际上，该公司的核心主张是在心脏电生理学的高度专业化领域增强信号清晰度和手术洞察力。（[globenewswire.com](https://www.globenewswire.com/news-release/2025/03/26/3049719/22558/en/biosig-technologies-confirms-full-compliance-with-nasdaq-requirements-for-continued-listing-on-the-nasdaq-capital-market.html?utm_source=openai)) BioSig 成立于 2010 年代中期，其形象是一家商业规模有限、需要经常外部资本的早期医疗技术开发商。这一形象在 2025 年发生了实质性变化。该公司宣布并完成了与 Streamex Exchange Corporation 的合并，此举将业务范围远远超出了医疗设备。Streamex 在公司通讯中被描述为一家黄金代币化基础设施公司，合并后的集团现在正致力于真实世界资产代币化、商品市场基础设施和黄金支持的国库计划。这使得 BSGM 成为一个比最初 BioSig 独立的医疗技术理论更广泛、更复杂的公开市场故事。（[globenewswire.com](https://www.globenewswire.com/news-release/2025/05/05/3074161/22558/en/biosig-enters-into-an-loi-to-merge-with-streamex-exchange-corp.html?utm_source=openai)) 从竞争角度来看，传统的 BioSig 业务在一个利基医疗设备类别中竞争，其成功取决于临床表现、监管进展和医院采纳。相比之下，新的 Streamex 业务在新兴的 RWA 代币化和数字资产基础设施领域竞争，尽管竞争仍在形成中，但执行、监管批准和金融市场合作伙伴关系至关重要。对于投资者而言，这意味着 BSGM 现在结合了两种截然不同的风险/回报框架：一个商业化时间线较长的小盘医疗技术平台，以及一个具有显著战略选择性但高度不确定性的早期金融技术/代币化计划。（[globenewswire.com](https://www.globenewswire.com/news-release/2025/09/08/3146210/22558/en/streamex-exchange-corp-nasdaq-bsgm-creates-a-tokenized-yield-bearing-gold-product-generating-up-to-4-through-exclusive-partnership-with-monetary-metals.html?utm_source=openai)) 近期公司发展是主要的市场催化剂。2025 年，BioSig 宣布了其 Streamex 交易，随后是融资计划、顾问任命以及纳斯达克合规性更新。该公司还在 2025 年 3 月表示，已完全符合纳斯达克上市要求，可在纳斯达克资本市场继续交易。后来的通讯强调了旨在支持黄金支持的国库战略并加速 RWA 代币化工作的增长融资。简而言之，BioSig 已从一家单一产品的医疗技术公司发展成为一家在纳斯达克上市的美国公司，奉行涵盖电生理技术、黄金挂钩国库管理和代币化商品市场基础设施的混合战略。（[globenewswire.com](https://www.globenewswire.com/news-release/2025/03/26/3049719/22558/en/biosig-technologies-confirms-full-compliance-with-nasdaq-requirements-for-continued-listing-on-the-nasdaq-capital-market.html?utm_source=openai))
